Purinergic Receptors in Basal Ganglia Diseases:Shared Molecular Mechanisms between Huntington’s and Parkinson’s Disease

作     者：Talita Glaser Roberta Andrejew Agatha Oliveira-Giacomelli Deidiane Elisa Ribeiro Lucas Bonfim Marques Qing Ye Wen-Jing Ren Alexey Semyanov Peter Illes Yong Tang Henning Ulrich Talita Glaser;Roberta Andrejew;(A)gatha Oliveira-Giacomelli;Deidiane Elisa Ribeiro;Lucas Bonfim Marques;Qing Ye;Wen-Jing Ren;Alexey Semyanov;Peter Illes;Yong Tang;Henning Ulrich

作者机构：Department of BiochemistryInstitute of ChemistryUniversity of Sao PauloAv.Prof.Lineu Prestes 74&Sao PauloSP 05508-000Brazil Key Laboratory of Sichuan Province for Acupuncture and ChronobiologyChengdu 610075China Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscow 117997Russia Sechenov First Moscow State Medical UniversityMoscow 119992Russia Rudolf-Boehm-Institut ftir Pharmakologie und ToxikologieUniversitat LeipzigLeipzig 04107Germany International Collaborative Centre on Big Science Plan for Purine SignalingChengdu University of Traditional Chinese MedicineChengdu 610075China 

出 版 物：《Neuroscience Bulletin》 (神经科学通报（英文版）)

年 卷 期：2020年第36卷第11期

页      面：1299-1314页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100204[医学-神经病学] 10[医学] 

基　　金：the Sao Paulo Research Foundation(FAPESP,2018/07366-4) a Fellowship from the National Council for Scientific and Technological Development(CNPq,306392/2017-8) postdoctoral fellowships from FAPESP(2015/13345-1,2019/268520,and 2018/17504-5) a doctoral fellowship from FAPESP(2019/24553-5) a master fellowship from CNPq(133396/2019-3) the fellowship from National Key R&D Program of China(2019YFC1709101) The Project First-Class Disciplines Development(CZYHW1901)of Chengdu University of TCM and Sichuan Science and Technology Program(2019YFH0108,2018SZ0257) supported by Russian Science Foundation grant 20-14-00241 

主　　题：Purinergic receptor Central nervous system Huntington’s disease Parkinson’s disease 6-hydroxydopamine 

摘      要：Huntington’s(HD)and Parkinson’s diseases(PD)are neurodegenerative disorders caused by the death of GABAergic and dopaminergic neurons in the basal ganglia leading to hyperkinetic and hypokinetic symptoms,*** review here the participation of purinergic receptors through intracellular Ca^2+signaling in these neurodegenerative *** adenosine A2A receptor stimulates striatopallidal GABAergic neurons,resulting in inhibitory actions on GABAergic neurons of the globus pallidus.A2A and dopamine D2 receptors form functional heteromeric complexes inducing allosteric inhibition,and A2A receptor activation results in motor ***,the A2A receptor physically and functionally interacts with glutamate receptors,mainly with the mGlu5 receptor *** interaction facilitates glutamate release,resulting in NMDA glutamate receptor activation and an increase of Ca2+influx.P2X7 receptor activation also promotes glutamate release and neuronal ***,modulation of purinergic receptor activity,such as A2A and P2X7 receptors,and subsequent aberrant Ca^2+signaling,might present interesting therapeutic potential for HD and PD.